Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Chantrill, Lorraine A., Nagrial, Adnan M., Watson, Clare, Johns, Amber L., Martyn-Smith, Mona, Simpson, Skye, Mead, Scott, Jones, Marc D., Samra, Jaswinder S., Gill, Anthony J., Watson, Nicole, Chin, Venessa T., Humphris, Jeremy L., Chou, Angela, Brown, Belinda, Morey, Adrienne, Pajic, Marina, Grimmond, Sean M., Chang, David K., Thomas, David, Sebastian, Lucille, Sjoquist, Katrin, Yip, Sonia, Pavlakis, Nick, Asghari, Ray, Harvey, Sandra, Grimison, Peter, Simes, John, Biankin, Andrew V.·2015·Clinical Cancer Research

Abstract

Purpose: Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices of the International Cancer Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets of patients with aberrations in their tumor genome that could be targeted with currently available therapies. Experimental Design: The pilot stage of the IMPaCT trial assessed the feasibility of acquiring suitable tumor specimens for molecular analysis and returning high-quality actionable genomic data within a clinically acceptable timeframe. We screened for three molecular targets: HER2 amplification; KRAS wild-type; and mutations in DNA damage repair pathways (BRCA1, BRCA2, PALB2, ATM). Results: Tumor biopsy and archived tumor samples were collected from 93 patients and 76 were screened. To date 22 candidate cases have been identified: 14 KRAS wild-type, 5 cases of HER2 amplification, 2 mutations in BRCA2, and 1 ATM mutation. Median time from consent to the return of validated results was 21.5 days. An inability to obtain a biopsy or insufficient tumor content in the available specimen were common reasons for patient exclusion from molecular analysis while deteriorating performance status prohibited a number of patients from proceeding in the study. Conclusions: Documenting the feasibility of acquiring and screening biospecimens for actionable molecular targets in real time will aid other groups embarking on similar trials. Key elements include the need to better prescreen patients, screen more patients, and offer more attractive clinical trial options. Clin Cancer Res; 21(9); 2029–37. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0426

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 238

Metadata

Authors
Chantrill, L. A., Nagrial, A. M., Watson, C., Johns, A. L., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M. D., Samra, J. S., Gill, A. J., Watson, N., Chin, V. T., Humphris, J. L., Chou, A., Brown, B., Morey, A., Pajic, M., Grimmond, S. M., Chang, D. K., Thomas, D., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Asghari, R., Harvey, S., Grimison, P., Simes, J., & Biankin, A. V.
Venue
Clinical Cancer Research
Published
2015-04-30
Volume
21
Issue
9
Pages
2029-2037
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1970383271
Cited by
238
References
3
FWCI
12.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0426
The paper
Chantrill, L. A., Nagrial, A. M., Watson, C., Johns, A. L., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M. D., Samra, J. S., Gill, A. J., Watson, N., Chin, V. T., Humphris, J. L., Chou, A., Brown, B., Morey, A., Pajic, M., Grimmond, S. M., Chang, D. K., . . . Biankin, A. V. (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.